Goodwin Procter LLP advised Vaccitech on the deal, while Davis Polk advised the representatives of the several underwriters. Vaccitech (Nasdaq: VACC) announced its initial public offering...
Vaccitech’s $110.5 Million Initial Public Offering
Vaccitech’s $168 Million Series B Financing Round
Goodwin Procter LLP advised Vaccitech on the deal. Vaccitech announced the completion of its $168 million Series B, including the conversion of $43 million in convertible loan...